INTEC PHARMA LTD. | ||
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS | ||
(Unaudited) | ||
Nine months ended | ||
September 30 | ||
2017 | 2018 | |
U.S. dollars | ||
in thousands | ||
APPENDIX A: | ||
Adjustments to reconcile loss and comprehensive loss to net cash used in operating activities: | ||
Income and expenses not involving cash flows: | ||
Depreciation | 613 | 639 |
Changes in the fair value of derivative financial instruments | 184 | - |
Exchange differences on cash and cash equivalents | (66) | (533) |
Exchange differences on restricted deposits | (6) | 5 |
Losses (gains) on financial assets at fair value through profit or loss | (168) | 141 |
Loss on sale of property and equipment | 2 | - |
Share-based compensation | 914 | 2,452 |
1,473 | 2,704 | |
Changes in operating asset and liability items: | ||
Decrease (increase) in other receivables | 1,051 | (979) |
Increase (decrease) in accounts payable and accruals | 1,373 | (1,734) |
2,424 | (2,713) | |
3,897 | (9) | |
APPENDIX B: | ||
Information regarding investment and financing activities not involving cash flows: | ||
Liability with respect to property purchase | 30 | 1,898 |
Liability with respect to other assets | - | 244 |
Settlement of liability in respect to derivative financial instrument to equity | 281 | - |
Supplementary information to the statement of cash flows: | ||
Taxes paid | - | 31 |
Interest received | 99 | 522 |
